These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 20560876)

  • 1. Targeted enzyme prodrug therapies.
    Schellmann N; Deckert PM; Bachran D; Fuchs H; Bachran C
    Mini Rev Med Chem; 2010 Sep; 10(10):887-904. PubMed ID: 20560876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodrugs in cancer chemotherapy.
    Connors TA; Knox RJ
    Stem Cells; 1995 Sep; 13(5):501-11. PubMed ID: 8528099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody directed enzyme prodrug therapy (ADEPT) and related approaches for anticancer therapy.
    Jung M
    Mini Rev Med Chem; 2001 Nov; 1(4):399-407. PubMed ID: 12369965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-step polymer- and liposome-enzyme prodrug therapies for cancer: PDEPT and PELT concepts and future perspectives.
    Scomparin A; Florindo HF; Tiram G; Ferguson EL; Satchi-Fainaro R
    Adv Drug Deliv Rev; 2017 Sep; 118():52-64. PubMed ID: 28916497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT).
    Niculescu-Duvaz I; Friedlos F; Niculescu-Duvaz D; Davies L; Springer CJ
    Anticancer Drug Des; 1999 Dec; 14(6):517-38. PubMed ID: 10834273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer.
    Connors TA
    Gene Ther; 1995 Dec; 2(10):702-9. PubMed ID: 8750009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prodrugs for targeted tumor therapies: recent developments in ADEPT, GDEPT and PMT.
    Tietze LF; Schmuck K
    Curr Pharm Des; 2011; 17(32):3527-47. PubMed ID: 22074425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Painting the target around the arrow: two-step prodrug therapies from a carbohydrate chemist's perspective.
    Houston TA
    Curr Drug Deliv; 2007 Oct; 4(4):264-8. PubMed ID: 17979645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective activation of anthracycline prodrugs for use in conjunction with ADEPT.
    HariKrishna D; Rao AR; Krishna DR
    Drug News Perspect; 2003 Jun; 16(5):309-18. PubMed ID: 12942162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for enzyme/prodrug cancer therapy.
    Xu G; McLeod HL
    Clin Cancer Res; 2001 Nov; 7(11):3314-24. PubMed ID: 11705842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted prodrug approaches for hormone refractory prostate cancer.
    Aloysius H; Hu L
    Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients.
    Vajda A; Marignol L; Foley R; Lynch TH; Lawler M; Hollywood D
    Cancer Treat Rev; 2011 Dec; 37(8):643-54. PubMed ID: 21481534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viral vectors for gene-directed enzyme prodrug therapy.
    Schepelmann S; Springer CJ
    Curr Gene Ther; 2006 Dec; 6(6):647-70. PubMed ID: 17168697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzyme/abzyme prodrug activation systems: potential use in clinical oncology.
    Nishi Y
    Curr Pharm Des; 2003; 9(26):2113-30. PubMed ID: 14529409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate.
    Smith GK; Banks S; Blumenkopf TA; Cory M; Humphreys J; Laethem RM; Miller J; Moxham CP; Mullin R; Ray PH; Walton LM; Wolfe LA
    J Biol Chem; 1997 Jun; 272(25):15804-16. PubMed ID: 9188478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in prodrug design.
    Silva AT; Chung MC; Castro LF; Güido RV; Ferreira EI
    Mini Rev Med Chem; 2005 Oct; 5(10):893-914. PubMed ID: 16250833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From bench to bedside for gene-directed enzyme prodrug therapy of cancer.
    Dachs GU; Tupper J; Tozer GM
    Anticancer Drugs; 2005 Apr; 16(4):349-59. PubMed ID: 15746571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody Directed Enzyme Prodrug Therapy (ADEPT): Trials and tribulations.
    Sharma SK; Bagshawe KD
    Adv Drug Deliv Rev; 2017 Sep; 118():2-7. PubMed ID: 28916498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Roy P; Waxman DJ
    Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction to the background, principles, and state of the art in suicide gene therapy.
    Niculescu-Duvaz I; Springer CJ
    Mol Biotechnol; 2005 May; 30(1):71-88. PubMed ID: 15805578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.